Journal:

Article Title: MICs of Mutacin B-Ny266, Nisin A, Vancomycin, and Oxacillin against Bacterial Pathogens

doi:

Figure Lengend Snippet: Activities of mutacin B-Ny266, nisin A, vancomycin, and oxacillin against gram-positive bacteria

Article Snippet: While many of the tested strains were resistant to nisin A, only S. epidermidis DSM 3095, producing epidermin, appeared less sensitive to mutacin B-Ny266 (Table ). table ft1 table-wrap mode="anchored" t5 TABLE 5 caption a7 Producing strain Lantibiotic produced MIC a (μg/ml) of: Mutacin B-Ny266 Nisin A Vancomycin Oxacillin Bacillus subtilis ATCC 6633 Subtilin 1.6 (1.0–1.6) 8.4 (8.4–10.5) 0.5 (0.3–0.5) 0.5 (0.5–0.5) Lactococcus lactis subsp. lactis ATCC 11454 Nisin A 1.0 (0.8–1.6) 27.2 (20.9–33.4) 0.5 (0.5–1.0) 2.1 (1.1–4.2) Lactococcus lactis subsp. lactis biovar diacetylactis UL719 Nisin Z 0.8 (0.8–1.6) 33.4 (33.4–41.8) 1.0 (0.5–1.0) 4.0 (3.0–4.2) Staphylococcus epidermidis DSM 3095 Epidermin 12.8 (8.7–18.1) 83.6 (66.9–83.6) 8.0 (7.5–15.1) 0.2 (0.1–0.3) Staphylococcus gallinarum DSM 4616 Gallidermin 1.6 (1.6–1.6) 2.1 (2.1–3.0) 2.0 (2.0–2.0) 0.8 (0.8–1.1) Streptococcus mutans BHT Mutacin b 0.8 (0.4–0.8) 16.7 (8.4–16.7) 0.5 (0.5–0.5) 0.2 (0.2–0.4) Streptococcus mutans 32K Mutalipocin 0.8 (0.8–1.6) 83.6 (41.8–83.6) 0.8 (0.5–1.0) 0.1 (0.1–0.3) Streptococcus mutans JH1140 Mutacin B-JH1140 1.6 (0.8–1.6) 41.8 (41.8–83.6) 1.0 (1.0–1.0) 0.05 (0.05–0.1) Streptococcus mutans Ny266 (ATCC 202022) Mutacin B-Ny266 4.8 (3.2–6.4) 33.4 (16.7–33.4) 1.0 (1.0–1.0) 0.1 (0.03–0.1) Open in a separate window a The MIC data are expressed as the median (range) obtained from at least three independent repetitions.

Techniques:

Journal:

Article Title: MICs of Mutacin B-Ny266, Nisin A, Vancomycin, and Oxacillin against Bacterial Pathogens

doi:

Figure Lengend Snippet: Activities of mutacin B-Ny266, nisin A, vancomycin, and oxacillin against gram-negative pathogens

Article Snippet: While many of the tested strains were resistant to nisin A, only S. epidermidis DSM 3095, producing epidermin, appeared less sensitive to mutacin B-Ny266 (Table ). table ft1 table-wrap mode="anchored" t5 TABLE 5 caption a7 Producing strain Lantibiotic produced MIC a (μg/ml) of: Mutacin B-Ny266 Nisin A Vancomycin Oxacillin Bacillus subtilis ATCC 6633 Subtilin 1.6 (1.0–1.6) 8.4 (8.4–10.5) 0.5 (0.3–0.5) 0.5 (0.5–0.5) Lactococcus lactis subsp. lactis ATCC 11454 Nisin A 1.0 (0.8–1.6) 27.2 (20.9–33.4) 0.5 (0.5–1.0) 2.1 (1.1–4.2) Lactococcus lactis subsp. lactis biovar diacetylactis UL719 Nisin Z 0.8 (0.8–1.6) 33.4 (33.4–41.8) 1.0 (0.5–1.0) 4.0 (3.0–4.2) Staphylococcus epidermidis DSM 3095 Epidermin 12.8 (8.7–18.1) 83.6 (66.9–83.6) 8.0 (7.5–15.1) 0.2 (0.1–0.3) Staphylococcus gallinarum DSM 4616 Gallidermin 1.6 (1.6–1.6) 2.1 (2.1–3.0) 2.0 (2.0–2.0) 0.8 (0.8–1.1) Streptococcus mutans BHT Mutacin b 0.8 (0.4–0.8) 16.7 (8.4–16.7) 0.5 (0.5–0.5) 0.2 (0.2–0.4) Streptococcus mutans 32K Mutalipocin 0.8 (0.8–1.6) 83.6 (41.8–83.6) 0.8 (0.5–1.0) 0.1 (0.1–0.3) Streptococcus mutans JH1140 Mutacin B-JH1140 1.6 (0.8–1.6) 41.8 (41.8–83.6) 1.0 (1.0–1.0) 0.05 (0.05–0.1) Streptococcus mutans Ny266 (ATCC 202022) Mutacin B-Ny266 4.8 (3.2–6.4) 33.4 (16.7–33.4) 1.0 (1.0–1.0) 0.1 (0.03–0.1) Open in a separate window a The MIC data are expressed as the median (range) obtained from at least three independent repetitions.

Techniques:

Journal:

Article Title: MICs of Mutacin B-Ny266, Nisin A, Vancomycin, and Oxacillin against Bacterial Pathogens

doi:

Figure Lengend Snippet: Activities of mutacin B-Ny266, nisin A, vancomycin, and oxacillin against antibiotic-resistant clinical and mouse isolates

Article Snippet: While many of the tested strains were resistant to nisin A, only S. epidermidis DSM 3095, producing epidermin, appeared less sensitive to mutacin B-Ny266 (Table ). table ft1 table-wrap mode="anchored" t5 TABLE 5 caption a7 Producing strain Lantibiotic produced MIC a (μg/ml) of: Mutacin B-Ny266 Nisin A Vancomycin Oxacillin Bacillus subtilis ATCC 6633 Subtilin 1.6 (1.0–1.6) 8.4 (8.4–10.5) 0.5 (0.3–0.5) 0.5 (0.5–0.5) Lactococcus lactis subsp. lactis ATCC 11454 Nisin A 1.0 (0.8–1.6) 27.2 (20.9–33.4) 0.5 (0.5–1.0) 2.1 (1.1–4.2) Lactococcus lactis subsp. lactis biovar diacetylactis UL719 Nisin Z 0.8 (0.8–1.6) 33.4 (33.4–41.8) 1.0 (0.5–1.0) 4.0 (3.0–4.2) Staphylococcus epidermidis DSM 3095 Epidermin 12.8 (8.7–18.1) 83.6 (66.9–83.6) 8.0 (7.5–15.1) 0.2 (0.1–0.3) Staphylococcus gallinarum DSM 4616 Gallidermin 1.6 (1.6–1.6) 2.1 (2.1–3.0) 2.0 (2.0–2.0) 0.8 (0.8–1.1) Streptococcus mutans BHT Mutacin b 0.8 (0.4–0.8) 16.7 (8.4–16.7) 0.5 (0.5–0.5) 0.2 (0.2–0.4) Streptococcus mutans 32K Mutalipocin 0.8 (0.8–1.6) 83.6 (41.8–83.6) 0.8 (0.5–1.0) 0.1 (0.1–0.3) Streptococcus mutans JH1140 Mutacin B-JH1140 1.6 (0.8–1.6) 41.8 (41.8–83.6) 1.0 (1.0–1.0) 0.05 (0.05–0.1) Streptococcus mutans Ny266 (ATCC 202022) Mutacin B-Ny266 4.8 (3.2–6.4) 33.4 (16.7–33.4) 1.0 (1.0–1.0) 0.1 (0.03–0.1) Open in a separate window a The MIC data are expressed as the median (range) obtained from at least three independent repetitions.

Techniques:

Journal:

Article Title: MICs of Mutacin B-Ny266, Nisin A, Vancomycin, and Oxacillin against Bacterial Pathogens

doi:

Figure Lengend Snippet: Activities of mutacin B-Ny266, nisin A, vancomycin, and oxacillin against nisin-resistant mutants

Article Snippet: While many of the tested strains were resistant to nisin A, only S. epidermidis DSM 3095, producing epidermin, appeared less sensitive to mutacin B-Ny266 (Table ). table ft1 table-wrap mode="anchored" t5 TABLE 5 caption a7 Producing strain Lantibiotic produced MIC a (μg/ml) of: Mutacin B-Ny266 Nisin A Vancomycin Oxacillin Bacillus subtilis ATCC 6633 Subtilin 1.6 (1.0–1.6) 8.4 (8.4–10.5) 0.5 (0.3–0.5) 0.5 (0.5–0.5) Lactococcus lactis subsp. lactis ATCC 11454 Nisin A 1.0 (0.8–1.6) 27.2 (20.9–33.4) 0.5 (0.5–1.0) 2.1 (1.1–4.2) Lactococcus lactis subsp. lactis biovar diacetylactis UL719 Nisin Z 0.8 (0.8–1.6) 33.4 (33.4–41.8) 1.0 (0.5–1.0) 4.0 (3.0–4.2) Staphylococcus epidermidis DSM 3095 Epidermin 12.8 (8.7–18.1) 83.6 (66.9–83.6) 8.0 (7.5–15.1) 0.2 (0.1–0.3) Staphylococcus gallinarum DSM 4616 Gallidermin 1.6 (1.6–1.6) 2.1 (2.1–3.0) 2.0 (2.0–2.0) 0.8 (0.8–1.1) Streptococcus mutans BHT Mutacin b 0.8 (0.4–0.8) 16.7 (8.4–16.7) 0.5 (0.5–0.5) 0.2 (0.2–0.4) Streptococcus mutans 32K Mutalipocin 0.8 (0.8–1.6) 83.6 (41.8–83.6) 0.8 (0.5–1.0) 0.1 (0.1–0.3) Streptococcus mutans JH1140 Mutacin B-JH1140 1.6 (0.8–1.6) 41.8 (41.8–83.6) 1.0 (1.0–1.0) 0.05 (0.05–0.1) Streptococcus mutans Ny266 (ATCC 202022) Mutacin B-Ny266 4.8 (3.2–6.4) 33.4 (16.7–33.4) 1.0 (1.0–1.0) 0.1 (0.03–0.1) Open in a separate window a The MIC data are expressed as the median (range) obtained from at least three independent repetitions.

Techniques:

Journal:

Article Title: MICs of Mutacin B-Ny266, Nisin A, Vancomycin, and Oxacillin against Bacterial Pathogens

doi:

Figure Lengend Snippet: Activities of mutacin B-Ny266, nisin A, vancomycin, and oxacillin against other lantibiotic-producing strains

Article Snippet: While many of the tested strains were resistant to nisin A, only S. epidermidis DSM 3095, producing epidermin, appeared less sensitive to mutacin B-Ny266 (Table ). table ft1 table-wrap mode="anchored" t5 TABLE 5 caption a7 Producing strain Lantibiotic produced MIC a (μg/ml) of: Mutacin B-Ny266 Nisin A Vancomycin Oxacillin Bacillus subtilis ATCC 6633 Subtilin 1.6 (1.0–1.6) 8.4 (8.4–10.5) 0.5 (0.3–0.5) 0.5 (0.5–0.5) Lactococcus lactis subsp. lactis ATCC 11454 Nisin A 1.0 (0.8–1.6) 27.2 (20.9–33.4) 0.5 (0.5–1.0) 2.1 (1.1–4.2) Lactococcus lactis subsp. lactis biovar diacetylactis UL719 Nisin Z 0.8 (0.8–1.6) 33.4 (33.4–41.8) 1.0 (0.5–1.0) 4.0 (3.0–4.2) Staphylococcus epidermidis DSM 3095 Epidermin 12.8 (8.7–18.1) 83.6 (66.9–83.6) 8.0 (7.5–15.1) 0.2 (0.1–0.3) Staphylococcus gallinarum DSM 4616 Gallidermin 1.6 (1.6–1.6) 2.1 (2.1–3.0) 2.0 (2.0–2.0) 0.8 (0.8–1.1) Streptococcus mutans BHT Mutacin b 0.8 (0.4–0.8) 16.7 (8.4–16.7) 0.5 (0.5–0.5) 0.2 (0.2–0.4) Streptococcus mutans 32K Mutalipocin 0.8 (0.8–1.6) 83.6 (41.8–83.6) 0.8 (0.5–1.0) 0.1 (0.1–0.3) Streptococcus mutans JH1140 Mutacin B-JH1140 1.6 (0.8–1.6) 41.8 (41.8–83.6) 1.0 (1.0–1.0) 0.05 (0.05–0.1) Streptococcus mutans Ny266 (ATCC 202022) Mutacin B-Ny266 4.8 (3.2–6.4) 33.4 (16.7–33.4) 1.0 (1.0–1.0) 0.1 (0.03–0.1) Open in a separate window a The MIC data are expressed as the median (range) obtained from at least three independent repetitions.

Techniques: Produced

Journal:

Article Title: Characterization of Staphylococci with Reduced Susceptibilities to Vancomycin and Other Glycopeptides

doi:

Figure Lengend Snippet: Comparison of vancomycin and teicoplanin MICs and disk diffusion zone sizes with the interpretive results for isolates of staphylococci exhibiting decreased susceptibility to glycopeptides

Article Snippet: Reduction of the vancomycin concentration to 4 or 2 μg/ml improved the detection of isolates for which the MICs were 8 μg/ml, but extensive growth of the susceptible isolates and quality control strains occurred. table ft1 table-wrap mode="anchored" t5 TABLE 6 caption a7 Screening plate content and isolate description No. of plates positive/total no. tested with medium a : Acumedia BBL Difco Oxoid Remel Vancomycin, 6 μg/ml Vancomycin MIC = 8 μg/ml 7/8 7/8 8/8 8/8 7/8 Vancomycin MIC = 4 μg/ml 1/3 b 2/3 b 1/3 b 1/3 b 1/3 b Vancomycin MIC ≤ 2 μg/ml 0/25 c 1/25 1/25 2/25 2/25 E. faecalis ATCC 51299 d 3/3 3/3 3/3 3/3 3/3 E. faecalis ATCC 29212 d 0/3 1/3 0/3 0/3 1/3 S. aureus ATCC 29213 d 0/3 3/3 0/3 2/3 1/3 S. aureus ATCC 25923 d 0/3 0/3 0/3 0/3 0/3 Vancomycin, 4 μg/ml Vancomycin MIC = 8 μg/ml 8/8 7/8 8/8 8/8 8/8 Vancomycin MIC = 4 μg/ml 1/3 2/3 1/3 1/3 1/3 Vancomycin MIC ≤ 2 μg/ml 3/25 7/25 2/25 3/25 13/25 E. faecalis ATCC 51299 3/3 3/3 3/3 3/3 3/3 E. faecalis ATCC 29212 0/3 0/3 0/3 1/3 3/3 S. aureus ATCC 29213 2/3 3/3 3/3 3/3 3/3 S. aureus ATCC 25923 0/3 0/3 0/3 0/3 0/3 Vancomycin, 2 μg/ml Vancomycin MIC = 8 μg/ml 8/8 8/8 8/8 8/8 8/8 Vancomycin MIC = 4 μg/ml 3/3 3/3 3/3 3/3 3/3 Vancomycin MIC ≤ 2 μg/ml 13/25 24/25 21/25 22/25 24/25 E. faecalis ATCC 51299 3/3 3/3 3/3 3/3 3/3 E. faecalis ATCC 29212 3/3 3/3 3/3 3/3 3/3 S. aureus ATCC 29213 3/3 3/3 3/3 3/3 3/3 S. aureus ATCC 25923 1/3 2/3 2/3 3/3 3/3 Open in a separate window a Sources of the media used for the screening plates are given. b S. aureus 966 (from Michigan), for which the vancomycin MIC was 4 μg/ml and for which the teicoplanin MIC was 16 μg/ml, was positive on all media. c Includes Mu3 (from Japan; reference MIC = 2 μg/ml). d Quality control isolates.

Techniques: Comparison, Diffusion-based Assay

Journal:

Article Title: Characterization of Staphylococci with Reduced Susceptibilities to Vancomycin and Other Glycopeptides

doi:

Figure Lengend Snippet: Distribution of disk diffusion zone diameters of Staphylococcus species obtained with a 30-μg vancomycin disk or a 30-μg teicoplanin disk. Discrepant results are (a) an S. epidermidis (GSSS) isolate for which the teicoplanin zone diameter was 13 mm and the teicoplanin MIC was 4 μg/ml, (b) an S. epidermidis (GSSS) isolate for which the teicoplanin zone diameter was 15 mm and the teicoplanin MIC was 4 μg/ml, and (c) an S. aureus (GISA) isolate (isolate N20) for which the teicoplanin zone diameter was 17 mm and the teicoplanin MIC was 1 μg/ml.

Article Snippet: Reduction of the vancomycin concentration to 4 or 2 μg/ml improved the detection of isolates for which the MICs were 8 μg/ml, but extensive growth of the susceptible isolates and quality control strains occurred. table ft1 table-wrap mode="anchored" t5 TABLE 6 caption a7 Screening plate content and isolate description No. of plates positive/total no. tested with medium a : Acumedia BBL Difco Oxoid Remel Vancomycin, 6 μg/ml Vancomycin MIC = 8 μg/ml 7/8 7/8 8/8 8/8 7/8 Vancomycin MIC = 4 μg/ml 1/3 b 2/3 b 1/3 b 1/3 b 1/3 b Vancomycin MIC ≤ 2 μg/ml 0/25 c 1/25 1/25 2/25 2/25 E. faecalis ATCC 51299 d 3/3 3/3 3/3 3/3 3/3 E. faecalis ATCC 29212 d 0/3 1/3 0/3 0/3 1/3 S. aureus ATCC 29213 d 0/3 3/3 0/3 2/3 1/3 S. aureus ATCC 25923 d 0/3 0/3 0/3 0/3 0/3 Vancomycin, 4 μg/ml Vancomycin MIC = 8 μg/ml 8/8 7/8 8/8 8/8 8/8 Vancomycin MIC = 4 μg/ml 1/3 2/3 1/3 1/3 1/3 Vancomycin MIC ≤ 2 μg/ml 3/25 7/25 2/25 3/25 13/25 E. faecalis ATCC 51299 3/3 3/3 3/3 3/3 3/3 E. faecalis ATCC 29212 0/3 0/3 0/3 1/3 3/3 S. aureus ATCC 29213 2/3 3/3 3/3 3/3 3/3 S. aureus ATCC 25923 0/3 0/3 0/3 0/3 0/3 Vancomycin, 2 μg/ml Vancomycin MIC = 8 μg/ml 8/8 8/8 8/8 8/8 8/8 Vancomycin MIC = 4 μg/ml 3/3 3/3 3/3 3/3 3/3 Vancomycin MIC ≤ 2 μg/ml 13/25 24/25 21/25 22/25 24/25 E. faecalis ATCC 51299 3/3 3/3 3/3 3/3 3/3 E. faecalis ATCC 29212 3/3 3/3 3/3 3/3 3/3 S. aureus ATCC 29213 3/3 3/3 3/3 3/3 3/3 S. aureus ATCC 25923 1/3 2/3 2/3 3/3 3/3 Open in a separate window a Sources of the media used for the screening plates are given. b S. aureus 966 (from Michigan), for which the vancomycin MIC was 4 μg/ml and for which the teicoplanin MIC was 16 μg/ml, was positive on all media. c Includes Mu3 (from Japan; reference MIC = 2 μg/ml). d Quality control isolates.

Techniques: Diffusion-based Assay

Journal:

Article Title: Characterization of Staphylococci with Reduced Susceptibilities to Vancomycin and Other Glycopeptides

doi:

Figure Lengend Snippet: Performance of commercial antimicrobial susceptibility test systems with staphylococcal study isolates

Article Snippet: Reduction of the vancomycin concentration to 4 or 2 μg/ml improved the detection of isolates for which the MICs were 8 μg/ml, but extensive growth of the susceptible isolates and quality control strains occurred. table ft1 table-wrap mode="anchored" t5 TABLE 6 caption a7 Screening plate content and isolate description No. of plates positive/total no. tested with medium a : Acumedia BBL Difco Oxoid Remel Vancomycin, 6 μg/ml Vancomycin MIC = 8 μg/ml 7/8 7/8 8/8 8/8 7/8 Vancomycin MIC = 4 μg/ml 1/3 b 2/3 b 1/3 b 1/3 b 1/3 b Vancomycin MIC ≤ 2 μg/ml 0/25 c 1/25 1/25 2/25 2/25 E. faecalis ATCC 51299 d 3/3 3/3 3/3 3/3 3/3 E. faecalis ATCC 29212 d 0/3 1/3 0/3 0/3 1/3 S. aureus ATCC 29213 d 0/3 3/3 0/3 2/3 1/3 S. aureus ATCC 25923 d 0/3 0/3 0/3 0/3 0/3 Vancomycin, 4 μg/ml Vancomycin MIC = 8 μg/ml 8/8 7/8 8/8 8/8 8/8 Vancomycin MIC = 4 μg/ml 1/3 2/3 1/3 1/3 1/3 Vancomycin MIC ≤ 2 μg/ml 3/25 7/25 2/25 3/25 13/25 E. faecalis ATCC 51299 3/3 3/3 3/3 3/3 3/3 E. faecalis ATCC 29212 0/3 0/3 0/3 1/3 3/3 S. aureus ATCC 29213 2/3 3/3 3/3 3/3 3/3 S. aureus ATCC 25923 0/3 0/3 0/3 0/3 0/3 Vancomycin, 2 μg/ml Vancomycin MIC = 8 μg/ml 8/8 8/8 8/8 8/8 8/8 Vancomycin MIC = 4 μg/ml 3/3 3/3 3/3 3/3 3/3 Vancomycin MIC ≤ 2 μg/ml 13/25 24/25 21/25 22/25 24/25 E. faecalis ATCC 51299 3/3 3/3 3/3 3/3 3/3 E. faecalis ATCC 29212 3/3 3/3 3/3 3/3 3/3 S. aureus ATCC 29213 3/3 3/3 3/3 3/3 3/3 S. aureus ATCC 25923 1/3 2/3 2/3 3/3 3/3 Open in a separate window a Sources of the media used for the screening plates are given. b S. aureus 966 (from Michigan), for which the vancomycin MIC was 4 μg/ml and for which the teicoplanin MIC was 16 μg/ml, was positive on all media. c Includes Mu3 (from Japan; reference MIC = 2 μg/ml). d Quality control isolates.

Techniques:

Journal:

Article Title: Characterization of Staphylococci with Reduced Susceptibilities to Vancomycin and Other Glycopeptides

doi:

Figure Lengend Snippet: Results of commercial vancomycin screening plates tested with staphylococcal isolates

Article Snippet: Reduction of the vancomycin concentration to 4 or 2 μg/ml improved the detection of isolates for which the MICs were 8 μg/ml, but extensive growth of the susceptible isolates and quality control strains occurred. table ft1 table-wrap mode="anchored" t5 TABLE 6 caption a7 Screening plate content and isolate description No. of plates positive/total no. tested with medium a : Acumedia BBL Difco Oxoid Remel Vancomycin, 6 μg/ml Vancomycin MIC = 8 μg/ml 7/8 7/8 8/8 8/8 7/8 Vancomycin MIC = 4 μg/ml 1/3 b 2/3 b 1/3 b 1/3 b 1/3 b Vancomycin MIC ≤ 2 μg/ml 0/25 c 1/25 1/25 2/25 2/25 E. faecalis ATCC 51299 d 3/3 3/3 3/3 3/3 3/3 E. faecalis ATCC 29212 d 0/3 1/3 0/3 0/3 1/3 S. aureus ATCC 29213 d 0/3 3/3 0/3 2/3 1/3 S. aureus ATCC 25923 d 0/3 0/3 0/3 0/3 0/3 Vancomycin, 4 μg/ml Vancomycin MIC = 8 μg/ml 8/8 7/8 8/8 8/8 8/8 Vancomycin MIC = 4 μg/ml 1/3 2/3 1/3 1/3 1/3 Vancomycin MIC ≤ 2 μg/ml 3/25 7/25 2/25 3/25 13/25 E. faecalis ATCC 51299 3/3 3/3 3/3 3/3 3/3 E. faecalis ATCC 29212 0/3 0/3 0/3 1/3 3/3 S. aureus ATCC 29213 2/3 3/3 3/3 3/3 3/3 S. aureus ATCC 25923 0/3 0/3 0/3 0/3 0/3 Vancomycin, 2 μg/ml Vancomycin MIC = 8 μg/ml 8/8 8/8 8/8 8/8 8/8 Vancomycin MIC = 4 μg/ml 3/3 3/3 3/3 3/3 3/3 Vancomycin MIC ≤ 2 μg/ml 13/25 24/25 21/25 22/25 24/25 E. faecalis ATCC 51299 3/3 3/3 3/3 3/3 3/3 E. faecalis ATCC 29212 3/3 3/3 3/3 3/3 3/3 S. aureus ATCC 29213 3/3 3/3 3/3 3/3 3/3 S. aureus ATCC 25923 1/3 2/3 2/3 3/3 3/3 Open in a separate window a Sources of the media used for the screening plates are given. b S. aureus 966 (from Michigan), for which the vancomycin MIC was 4 μg/ml and for which the teicoplanin MIC was 16 μg/ml, was positive on all media. c Includes Mu3 (from Japan; reference MIC = 2 μg/ml). d Quality control isolates.

Techniques:

Journal:

Article Title: Characterization of Staphylococci with Reduced Susceptibilities to Vancomycin and Other Glycopeptides

doi:

Figure Lengend Snippet: Results of testing with vancomycin screening agar prepared in-house

Article Snippet: Reduction of the vancomycin concentration to 4 or 2 μg/ml improved the detection of isolates for which the MICs were 8 μg/ml, but extensive growth of the susceptible isolates and quality control strains occurred. table ft1 table-wrap mode="anchored" t5 TABLE 6 caption a7 Screening plate content and isolate description No. of plates positive/total no. tested with medium a : Acumedia BBL Difco Oxoid Remel Vancomycin, 6 μg/ml Vancomycin MIC = 8 μg/ml 7/8 7/8 8/8 8/8 7/8 Vancomycin MIC = 4 μg/ml 1/3 b 2/3 b 1/3 b 1/3 b 1/3 b Vancomycin MIC ≤ 2 μg/ml 0/25 c 1/25 1/25 2/25 2/25 E. faecalis ATCC 51299 d 3/3 3/3 3/3 3/3 3/3 E. faecalis ATCC 29212 d 0/3 1/3 0/3 0/3 1/3 S. aureus ATCC 29213 d 0/3 3/3 0/3 2/3 1/3 S. aureus ATCC 25923 d 0/3 0/3 0/3 0/3 0/3 Vancomycin, 4 μg/ml Vancomycin MIC = 8 μg/ml 8/8 7/8 8/8 8/8 8/8 Vancomycin MIC = 4 μg/ml 1/3 2/3 1/3 1/3 1/3 Vancomycin MIC ≤ 2 μg/ml 3/25 7/25 2/25 3/25 13/25 E. faecalis ATCC 51299 3/3 3/3 3/3 3/3 3/3 E. faecalis ATCC 29212 0/3 0/3 0/3 1/3 3/3 S. aureus ATCC 29213 2/3 3/3 3/3 3/3 3/3 S. aureus ATCC 25923 0/3 0/3 0/3 0/3 0/3 Vancomycin, 2 μg/ml Vancomycin MIC = 8 μg/ml 8/8 8/8 8/8 8/8 8/8 Vancomycin MIC = 4 μg/ml 3/3 3/3 3/3 3/3 3/3 Vancomycin MIC ≤ 2 μg/ml 13/25 24/25 21/25 22/25 24/25 E. faecalis ATCC 51299 3/3 3/3 3/3 3/3 3/3 E. faecalis ATCC 29212 3/3 3/3 3/3 3/3 3/3 S. aureus ATCC 29213 3/3 3/3 3/3 3/3 3/3 S. aureus ATCC 25923 1/3 2/3 2/3 3/3 3/3 Open in a separate window a Sources of the media used for the screening plates are given. b S. aureus 966 (from Michigan), for which the vancomycin MIC was 4 μg/ml and for which the teicoplanin MIC was 16 μg/ml, was positive on all media. c Includes Mu3 (from Japan; reference MIC = 2 μg/ml). d Quality control isolates.

Techniques: